1. Scrip
  2. >>Therapy Areas

Cutanea acquisition to bolster Maruho's US presence

 
• By Ian Haydock

Maruho has acquired 100% of the private US firm Cutanea Life Sciences, apparently taking advantage of the strength of the yen to expand its business interests and capabilities in the US.

Maruho has acquired 100% of the private US firm Cutanea Life Sciences, apparently taking advantage of the strength of the yen to expand its business interests and capabilities in the US.

The Japanese topical dermatology specialist has so far had only a limited presence outside its home market, although it converted an office in New York into a US

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

More from Therapeutic Category

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.